Collegium Pharmaceutical (NASDAQ:COLL) Hits New 1-Year Low Following Analyst Downgrade

Key Points

• Collegium Pharmaceutical shares fell to a new 52-week low, trading as low as $28.90 after Needham cut its price target from $56 to $46, though it maintained a Buy rating. Analysts’ average rating remains “Moderate Buy,” with an average price target of $55.
• The company reported strong second-quarter results, with adjusted EPS of $1.92 exceeding estimates and revenue rising 6% year over year to about $199.9 million. JORNAY PM sales grew 41%, while the newly acquired AZSTARYS added $12.9 million in partial-quarter revenue.
• Management lowered 2026 revenue and adjusted EBITDA guidance, citing weaker Nucynta authorized-generic sales and lower net pricing. The pain portfolio declined 9%, and Collegium reported a $15.1 million GAAP net loss compared with a profit a year earlier.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Friday after Needham & Company LLC lowered their price target on the stock from $56.00 to $46.00. Needham & Company LLC currently has a buy rating on the stock. Collegium Pharmaceutical traded as low as $28.90 and last traded at $29.11, with a volume of 2131636 shares traded. The stock had previously closed at $35.74.

A number of other analysts have also weighed in on COLL. Zacks Research lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Weiss Ratings reiterated a "hold (c)" rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Truist Financial upgraded shares of Collegium Pharmaceutical to a "strong-buy" rating in a report on Monday, June 15th. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $55.00.

Trending Headlines about Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Second-quarter adjusted EPS was $1.92, exceeding the $1.72 analyst consensus and rising from $1.68 a year earlier. Revenue increased 6% year over year to approximately $199.9 million, slightly above estimates. Collegium Q2 earnings beat
• Positive Sentiment: JORNAY PM revenue grew 41% to $46.1 million, while the newly acquired AZSTARYS contributed $12.9 million in partial-quarter sales. Collegium completed the AZSTARYS acquisition, adding a complementary ADHD treatment with expected patent protection through 2037. Collegium Q2 financial results
• Positive Sentiment: Operating cash flow was $71.3 million, and adjusted EBITDA rose 8% year over year to $113.8 million, supporting the company’s ability to fund operations and integrate AZSTARYS.
• Neutral Sentiment: Needham maintained a Buy rating but lowered its price target from $56 to $46, reflecting a more cautious outlook while still implying substantial potential upside from recent trading levels. Needham price target update
• Negative Sentiment: Collegium reduced 2026 product-revenue guidance to $825 million-$855 million from $865 million-$895 million and cut adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. Management attributed the reductions mainly to weaker-than-expected Nucynta authorized-generic revenue and lower net pricing.
• Negative Sentiment: The pain portfolio declined 9% to $140.9 million, including a 24% drop in Nucynta revenue and a 14% decline in Xtampza ER. GAAP results also shifted to a $15.1 million net loss from $12.0 million of profit, while operating expenses rose 45%, partly due to acquisition-related costs. Collegium Q2 2026 earnings call transcript

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COLL. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical during the fourth quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company's stock valued at $29,000 after buying an additional 427 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 318 shares in the last quarter.

Collegium Pharmaceutical Price Performance

The company's 50 day moving average is $34.86 and its 200 day moving average is $37.13. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $944.04 million, a price-to-earnings ratio of 14.27 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. During the same quarter in the prior year, the firm posted $1.68 earnings per share. Collegium Pharmaceutical's revenue for the quarter was up 6.3% on a year-over-year basis. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source